Welcome to our dedicated page for Inmode news (Ticker: INMD), a resource for investors and traders seeking the latest updates and insights on Inmode stock.
InMode Ltd. reports developments in medical-technology devices that use radiofrequency technology for minimally invasive and non-invasive aesthetic and medical procedures. Company updates commonly address product platforms and treatment categories for plastic surgery, dermatology, gynecology, otolaryngology and ophthalmology, including face and body contouring, medical aesthetics and women's health.
Recurring news also covers GAAP and non-GAAP financial results, consumables and service revenue, regional performance in the United States and Europe, margin trends, investor-conference participation, board-reviewed strategic matters and capital allocation actions such as ordinary-share repurchase programs.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
InMode Ltd. (INMD) announced the expected release of its first-quarter 2023 financial results on May 2, 2023, before the Nasdaq market opens. Preliminary estimates indicate revenue between $105.7 million and $105.9 million, and non-GAAP earnings per diluted share in the range of $0.50 to $0.51. The company anticipates a non-GAAP gross margin between 83% and 85%. The management team will host a conference call at 8:30 a.m. Eastern Time to discuss the financial results. Investors are encouraged to register for the call ahead of time.